Modular Medical Announces First Human Use of MODD1 Pump to Deliver Insulin.
PorAinvest
miércoles, 6 de agosto de 2025, 8:12 am ET1 min de lectura
MODD--
The MODD1 pump, designed specifically to target the estimated $3 billion adult "almost-pumpers" market, has been cleared by the U.S. Food and Drug Administration (FDA) for human use. The pump is currently delivering insulin to a clinician with Type 1 diabetes under FDA institutional review board approval. The company plans to expand testing to multiple clinicians across multiple sites in mid-August 2025 [2].
The MODD1 pump's controller module is identical to that of Modular Medical's tubeless Pivot model, demonstrating the company's strategy of leveraging shared technology across multiple product lines. This approach not only accelerates development timelines but also reduces costs [2].
Jeb Besser, CEO of Modular Medical, commented, "This is another step in the maturation of the Modular Medical patch pump delivery platform. The pump controller module for MODD1 and the tubeless Pivot are identical, and the successful delivery of insulin has been a milestone we have anticipated since we began development."
Modular Medical's focus on a user-friendly and affordable design aims to address the limitations of current insulin delivery systems that have prevented wider adoption among patients who could benefit from pump therapy [2].
The company's successful human testing phase represents one of the final steps before potential commercial deployment, though regulatory requirements for expanded use will need to be satisfied before full market release. This methodical approach—starting with a single clinician before expanding—aligns with best practices in medical device development by allowing for controlled assessment before broader deployment [2].
References
[1] https://www.newswire.com/news/modular-medical-announces-modd1-cartridge-line-validated-for-human-use
[2] https://www.stocktitan.net/news/MODD/modular-medical-announces-first-human-use-of-modd1-pump-delivering-y9zn4o8av6vc.html
Modular Medical has announced the first human use of its MODD1 pump to deliver insulin to a person with Type 1 diabetes. The pump has been cleared by the FDA and is intended for the adult "almost-pumpers" market. The company plans to deploy the pump on multiple clinicians in mid-August. The MODD1 is designed to target the estimated $3 billion adult market with its user-friendly and affordable design.
San Diego, CA — Modular Medical, Inc. (Nasdaq: MODD), a leading insulin delivery technology company, has announced a significant milestone in its commercialization journey. The company has successfully conducted the first human use of its MODD1 insulin pump to deliver insulin to a person with Type 1 diabetes, marking a crucial step towards broader market deployment [2].The MODD1 pump, designed specifically to target the estimated $3 billion adult "almost-pumpers" market, has been cleared by the U.S. Food and Drug Administration (FDA) for human use. The pump is currently delivering insulin to a clinician with Type 1 diabetes under FDA institutional review board approval. The company plans to expand testing to multiple clinicians across multiple sites in mid-August 2025 [2].
The MODD1 pump's controller module is identical to that of Modular Medical's tubeless Pivot model, demonstrating the company's strategy of leveraging shared technology across multiple product lines. This approach not only accelerates development timelines but also reduces costs [2].
Jeb Besser, CEO of Modular Medical, commented, "This is another step in the maturation of the Modular Medical patch pump delivery platform. The pump controller module for MODD1 and the tubeless Pivot are identical, and the successful delivery of insulin has been a milestone we have anticipated since we began development."
Modular Medical's focus on a user-friendly and affordable design aims to address the limitations of current insulin delivery systems that have prevented wider adoption among patients who could benefit from pump therapy [2].
The company's successful human testing phase represents one of the final steps before potential commercial deployment, though regulatory requirements for expanded use will need to be satisfied before full market release. This methodical approach—starting with a single clinician before expanding—aligns with best practices in medical device development by allowing for controlled assessment before broader deployment [2].
References
[1] https://www.newswire.com/news/modular-medical-announces-modd1-cartridge-line-validated-for-human-use
[2] https://www.stocktitan.net/news/MODD/modular-medical-announces-first-human-use-of-modd1-pump-delivering-y9zn4o8av6vc.html
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios